Califf briefly served as FDA commissioner toward the end of President Barack Obama’s administration.
Biden pledges to lower prescription drug prices for Americans
Dec 07, 2021
But the biggest policy change — letting Medicare negotiate prices for prescription drugs — will not start to lower costs until 2025.
FDA approves first treatment for Alzheimer’s in 18 years
By
Kimberly Bonvissuto
Jun 07, 2021
The first novel therapy for Alzheimer’s disease in almost two decades was approved today by the Food & Drug Administration.
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
Bipartisan group of 23 state AGs joins call for unrestricted coverage of Alzheimer’s treatments
By
Kimberly Bonvissuto
May 03, 2023
A bipartisan group of attorneys general from 23 states have joined a growing chorus calling on Medicare to reverse a previous decision and provide unrestricted coverage of Food and Drug Administration-approved...
Lawmakers chide HHS for ‘eroding the pathway’ to Alzheimer’s treatments
By
Kimberly Bonvissuto
Mar 24, 2023
With personal stories of the effects that Alzheimer’s disease has had on them, lawmakers in a Senate Finance Committee hearing on Wednesday called for the federal government to speed up access to treatments....
Lawmakers turn up heat on CMS to expand access to Alzheimer’s treatments
By
Kimberly Bonvissuto
Apr 28, 2023
Medicare needs to reconsider its national coverage decision on FDA-approved Alzheimer’s drug treatments, bipartisan members of the House told Centers for Medicare & Medicaid Services Administrator Chiquita...
Legislation aims to ensure ‘fair and accurate’ Alzheimer’s treatment coverage decisions
By
Kimberly Bonvissuto
Nov 21, 2023
Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.